Quanterix (NASDAQ:QTRX – Get Free Report) and IM Cannabis (NASDAQ:IMCC – Get Free Report) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their profitability, valuation, dividends, earnings, institutional ownership, analyst recommendations and risk.
Institutional and Insider Ownership
86.5% of Quanterix shares are owned by institutional investors. Comparatively, 7.7% of IM Cannabis shares are owned by institutional investors. 6.8% of Quanterix shares are owned by insiders. Comparatively, 5.9% of IM Cannabis shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
Profitability
This table compares Quanterix and IM Cannabis’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Quanterix | -77.14% | -23.96% | -17.86% |
| IM Cannabis | -9.47% | -134.35% | -11.66% |
Risk & Volatility
Valuation & Earnings
This table compares Quanterix and IM Cannabis”s gross revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Quanterix | $138.90 million | 1.53 | -$107.15 million | ($2.52) | -1.79 |
| IM Cannabis | $39.44 million | 0.09 | -$7.72 million | ($0.78) | -0.79 |
IM Cannabis has lower revenue, but higher earnings than Quanterix. Quanterix is trading at a lower price-to-earnings ratio than IM Cannabis, indicating that it is currently the more affordable of the two stocks.
Analyst Recommendations
This is a summary of recent ratings and recommmendations for Quanterix and IM Cannabis, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Quanterix | 1 | 2 | 1 | 0 | 2.00 |
| IM Cannabis | 1 | 0 | 0 | 0 | 1.00 |
Quanterix currently has a consensus price target of $11.33, suggesting a potential upside of 150.74%. Given Quanterix’s stronger consensus rating and higher possible upside, research analysts plainly believe Quanterix is more favorable than IM Cannabis.
Summary
Quanterix beats IM Cannabis on 8 of the 14 factors compared between the two stocks.
About Quanterix
Quanterix Corporation, a life sciences company, engages in development and marketing of digital immunoassay platforms that advances precision health for life sciences research and diagnostics in North America, Europe, the Middle East, Africa, and the Asia Pacific regions. The company offers HD-X instrument, a protein detection platform; and SR-X instrument that enables researchers to apply Simoa detection in an expanded range of applications. It also provides SP-X instrument that is based on Simoa planar array technology for the measurement of multiplex chemiluminescent immunoassays. The company's products include assays include all components required to run enzyme-based immunoassay, such as beads, capture and detector reagents, and enzyme reagents and substrate; and replacement parts, reagents, and antibodies. In addition, it offers contract research services, including sample testing, homebrew assay development, custom assay development, lucent diagnostic, and LDT testing services. The company primarily operates in the areas of neurology, oncology, cardiology, infectious diseases, and inflammation. It sells its products for the life science research sector primarily to laboratories associated with academic and governmental research institutions, as well as pharmaceutical, biotechnology, and contract research companies through a direct field sale, support organizations, and distributors or sales agents. The company was formerly known as Digital Genomics, Inc. and changed its name to Quanterix Corporation in August 2007. Quanterix Corporation was incorporated in 2007 and is headquartered in Billerica, Massachusetts.
About IM Cannabis
IM Cannabis Corp. engages in breeding, growing, and supply of medical cannabis products in Israel and Germany. It offers cannabis flowers and strain-specific cannabis extracts under the IMC brand; and dried flower, pre-rolls, minis, and full spectrum extracts offerings under the WAGNERS and BLKMKT brands. The company serves medical patients. IM Cannabis Corp. is headquartered in Tel Aviv, Israel.
Receive News & Ratings for Quanterix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Quanterix and related companies with MarketBeat.com's FREE daily email newsletter.
